Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Chemotherapy With or Without Bevacizumab in Patients With Resected Hepatic Metastases From Colorectal Cancer

PURPOSE: Add systemic bevacizumab (Bev) to adjuvant hepatic arterial infusion (HAI) plus systemic therapy after liver resection to increase recurrence-free survival (RFS). PATIENTS AND METHODS: Patients were randomly assigned to HAI plus systemic therapy with or without Bev. If 1-year RFS of ≥ 80% w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kemeny, Nancy E., Jarnagin, William R., Capanu, Marinela, Fong, Yuman, Gewirtz, Alexandra N., DeMatteo, Ronald P., D'Angelica, Michael I.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2011
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3646323/
https://ncbi.nlm.nih.gov/pubmed/21189384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.32.5977
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados